for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mylan NV

MYL.O

Latest Trade

16.06USD

Change

0.30(+1.90%)

Volume

170,918

Today's Range

15.98

 - 

16.14

52 Week Range

12.75

 - 

23.11

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.76
Open
16.00
Volume
170,918
3M AVG Volume
138.79
Today's High
16.14
Today's Low
15.98
52 Week High
23.11
52 Week Low
12.75
Shares Out (MIL)
516.95
Market Cap (MIL)
8,144.50
Forward P/E
3.58
Dividend (Yield %)
--

Next Event

Q2 2020 Mylan NV Earnings Release

Latest Developments

More

Mylan Shareholders Overwhelmingly Approve Proposed Combination With Upjohn

Biogen Says To Appeal Court Decision Regarding Patent Related To Tecfidera

U.S. District Court Finds Mylan Has Convincing Evidence That Asserted Claims By Biogen For Patent Associated With Tecfidera Are Invalid

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mylan NV

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The Company's Cold-EEZE family of brands includes OTC cold remedies sold as lozenges, gummies, oral sprays, caplets, QuickMelts and oral liquid dose forms in the United States. The North America segment primarily develops, manufactures, sells and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream or ointment form. The Europe segment sells pharmaceuticals under their International Nonproprietary Name (INN), such as active pharmaceutical ingredient (API), in certain European countries. The Rest of World segment is primarily made up of its operations in India, Australia, Japan and New Zealand.

Industry

Biotechnology & Drugs

Contact Info

Unit 4, Trident Place, Mosquito Way

AL10 9UL

United Kingdom

+44.1707.853000

https://www.mylan.com

Executive Leadership

Robert J. Coury

Executive Chairman of the Board

Rajiv Malik

President, Executive Director

Heather M. Bresch

Chief Executive Officer, Executive Director

Mark W. Parrish

Lead Independent Non-Executive Vice Chairman of the Board

Robert J. Cindrich

Non-Executive Independent Director

Key Stats

2.35 mean rating - 17 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

11.9K

2018

11.4K

2019

11.5K

2020(E)

11.7K
EPS (USD)

2017

4.560

2018

4.580

2019

4.420

2020(E)

4.395
Price To Earnings (TTM)
130.74
Price To Sales (TTM)
0.70
Price To Book (MRQ)
0.72
Price To Cash Flow (TTM)
4.08
Total Debt To Equity (MRQ)
112.16
LT Debt To Equity (MRQ)
99.42
Return on Investment (TTM)
0.24
Return on Equity (TTM)
0.20

Latest News

Latest News

BRIEF-Mylan Shareholders Overwhelmingly Approve Proposed Combination With Upjohn

* MYLAN SHAREHOLDERS OVERWHELMINGLY APPROVE PROPOSED COMBINATION WITH UPJOHN

U.S. court rules in favor of Mylan over Biogen's key MS drug patent

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%.

BRIEF-U.S. District Court Finds Mylan Has Convincing Evidence That Asserted Claims By Biogen For Patent Associated With Tecfidera Are Invalid

* U.S. DISTRICT COURT FINDS MYLAN HAS CONVINCING EVIDENCE THAT ASSERTED CLAIMS BY BIOGEN FOR PATENT ASSOCIATED WITH TECFIDERA ARE INVALID

U.S. district court rules for Mylan in MS drug patent battle with Biogen

A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV in a patent dispute over Biogen Inc's blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker's shares down 7%.

BRIEF-Mylan Continues To Target About $1 Billion Of Debt Repayment During 2020

* MYLAN - CONTINUES TO TARGET ABOUT $1 BILLION OF DEBT REPAYMENT DURING 2020 Source text: (https://bit.ly/3fyrqIm) Further company coverage:

BRIEF-Mylan NV Says CEO's 2019 Total Compensation Was $18.5 Mln Vs $13.3 Mln In 2018 – SEC Filing

* MYLAN NV SAYS CEO HEATHER BRESCH'S 2019 TOTAL COMPENSATION WAS $18.5 MILLION VERSUS $13.3 MILLION IN 2018 – SEC FILING

BRIEF-Mylan And Lupin Receive European Marketing Authorization For Nepexto, Biosimilar Etanercept

* MYLAN AND LUPIN RECEIVE EUROPEAN MARKETING AUTHORIZATION FOR NEPEXTO®, BIOSIMILAR ETANERCEPT Source text for Eikon: Further company coverage:

BRIEF-Lupin And Mylan Receive European Marketing Authorization For Nepexto, Biosimilar Etanercept

* LUPIN AND MYLAN RECEIVE EUROPEAN MARKETING AUTHORIZATION FOR NEPEXTO, BIOSIMILAR ETANERCEPT Source text for Eikon: Further company coverage:

BRIEF-Revance And Mylan To Advance Development Program For Biosimilar To Botox

* REVANCE AND MYLAN TO ADVANCE DEVELOPMENT PROGRAM FOR BIOSIMILAR TO BOTOX®

BRIEF-Mylan Invalidates Sanofi's Lantus Solostar Device Patents In IPR Proceedings

* MYLAN INVALIDATES SANOFI'S LANTUS® SOLOSTAR® DEVICE PATENTS IN IPR PROCEEDINGS

BRIEF-Gilead Says Signed Non-Exclusive Voluntary Licensing Agreements With 5 Generic Pharmaceutical Manufacturers Based In India, Pakistan To Further Expand Supply Of Remdesivir

* GILEAD SCIENCES - SIGNED NON-EXCLUSIVE VOLUNTARY LICENSING AGREEMENTS WITH 5 GENERIC PHARMACEUTICAL MANUFACTURERS BASED IN INDIA, PAKISTAN TO FURTHER EXPAND SUPPLY OF REMDESIVIR

BRIEF-Mylan NV Exec Says In A Strong Position To Cater To Epipen Demand Ahead Of Back-To-School Season Conf. Call

* EXECUTIVE SAYS OPERATIONS IN INDIA DID NOT EXPERIENCE MUCH DISRUPTION DESPITE LOCKDOWN: CONF. CALL

Mylan beats profit on COVID-19 stockpiling, maintains forecast

Mylan NV <MYL.O> beat analysts' estimates for quarterly profit as it benefited from customers stocking up on its cold and asthma medicines ahead of lockdowns imposed to curb the spread of the coronavirus and maintained its 2020 revenue forecast.

BRIEF-Mylan Reports First Quarter 2020 Results And Reaffirms 2020 Guidance

* MYLAN REPORTS FIRST QUARTER 2020 RESULTS AND REAFFIRMS 2020 GUIDANCE

Mylan first-quarter revenue jumps 5% on drug stockpiling

Mylan NV reported a 5% jump in quarterly revenue on Monday, as customers stocked up on its medicines before hunkering down in their homes to curb the spread of the coronavirus.

BRIEF-Revance And Mylan Biosimilar To Botox Program Decision To Extend Beyond April 30, 2020

* REVANCE AND MYLAN BIOSIMILAR TO BOTOX® PROGRAM DECISION TO EXTEND BEYOND APRIL 30, 2020

BRIEF-Mylan CEO FY 2019 Total Compenstion Was $18.5 Mln Versus $13.3 Mln In FY 2018

* MYLAN NV SAYS CEO HEATHER BRESCH'S FY 2019 TOTAL COMPENSTION WAS $18.5 MILLION VERSUS $13.3 MILLION IN FY 2018 - SEC FILING

BRIEF-Biocon Says Co, Mylan Launch Fulphila, Biosimilar Pegfilgrastim In Canada

* BIOCON LTD SAYS BIOCON AND MYLAN LAUNCH FULPHILA, BIOSIMILAR PEGFILGRASTIM, IN CANADA Source text for Eikon: Further company coverage:

EU clears Mylan's purchase of Pfizer's Upjohn unit with conditions

The European Commission said on Wednesday it had approved generic drugmaker Mylan NV's <MYL.O> planned purchase of Pfizer's <PFE.N> off-patient branded drugs business Upjohn, subject to conditions.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up